New Study by Yale University Raises Concerns About E-Cigarettes

News by 2FIRSTS.ai
Aug.13.2024
New Study by Yale University Raises Concerns About E-Cigarettes
Yale study reveals some e-cigarettes may contain potent nicotine-like chemicals, raising health concerns beyond FDA regulation.

According to a report by Newsweek on August 12, a previous study by Yale University found that some e-cigarettes may contain chemical compounds similar to nicotine that could have unknown effects on health.


These nicotine alternatives interact with receptors in the brain, without being subject to FDA restrictions and regulations. As a result, these products are able to be marketed with flavors that appeal to young people and avoid tobacco taxes.


An FDA spokesperson stated that these new chemicals may be more potent than nicotine and could potentially affect the brain development, learning abilities, and memory of adolescents.


FDA Public Affairs Specialist Jim McKinney told Newsweek that...


The FDA is addressing this issue from the perspective of the entire agency and will continue to utilize all resources within its authority to protect the public, especially American adolescents, from potentially harmful addictive products.


McKinney points out that, although more research is needed, some emerging data suggests that these nicotine analogs may be more potent than nicotine itself, which is already highly addictive, altering adolescent brain development and producing long-term effects.


According to research, nicotine analogs are chemical substances that are structurally very similar to nicotine and therefore target the same receptors in the brain. Examples include 6-methyl nicotine and nicotineamide. A study in rodents suggests that 6-methyl nicotine may be more toxic than nicotine. Furthermore, because these compounds are not subject to the same strict regulations as traditional nicotine, the ingredients listed on labels may not always match the actual ingredients in the products.


Dr. Hanno Erythropel, a scientist at the Yale School of Medicine, stated in a press release,


In conclusion, the company is actually trying to evade regulation by introducing new products containing nicotine analogues with unknown health and addiction risks.


In a study published in the journal "JAMA Network," the researcher and their colleagues analyzed two e-cigarette and e-liquid products on the market. The first product, Spree Bar, claimed to contain 5% of 6-methyl nicotine (50 milligrams/gram), while the second product, Nic-Safe, was tested at four concentrations—0, 12, 24, and 36 milligrams/milliliter.


The research results show that both products do not contain the ingredients as specified on their labels. Spree Bar actually contains 90% less 6-methyl nicotine than advertised, while Nic-Safe contains a low concentration of 6-methyl nicotine without it being clearly marked on the label (excluding tested nicotine-free products).


FDA spokesperson Mackinney said that


In general, the FDA does not comment on specific studies, but instead uses them as part of the evidence to further understand specific issues and help achieve its mission of protecting public health. Regarding nicotine mimetics, the FDA is aware that some companies are reported to be producing products that may contain compounds with chemical structures or properties different from nicotine.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary's government announced on November 18, 2026, plans to terminate the exclusive tobacco retail supply concession held by Országos Dohányboltellátó (ODBE) on June 1, 2027, approximately eight years before the contract's scheduled expiry in 2035. ODBE is owned 49% by a Hungarian subsidiary of British American Tobacco (BAT) and 51% by Tabán Trafik. It has served as the exclusive supplier to Hungary's licensed tobacco retail network since 2015. The proposed legislation would end the concession without compensation and allow other qualified suppliers and tobacco wholesalers to serve retailers directly. ODBE generated HUF 67.3 billion (approximately $200 million) in after-tax profit between 2015 and 2025 and distributed nearly HUF 64 billion ($191 million) in dividends. The bill also proposes changes to retail margins, inventory rules, payment arrangements and procurement penalties, including those affecting heated tobacco products.
company
Nov.19 by 2Firsts Perspectives